CSIMarket Company Name, Ticker, Competitors, else..
 
Aveo Pharmaceuticals Inc   (AVEO)
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 35
 Employees -
 Revenues (TTM) (Millions $) 95
 Net Income (TTM) (Millions $) -29
 Cash Flow (TTM) (Millions $) 9
 Capital Exp. (TTM) (Millions $) 0

Business Description


Aveo Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing targeted cancer therapies. The company primarily focuses on developing medicines that inhibit the growth and spread of tumors and improve patients' outcomes. Their primary product candidate is tivozanib, a vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, which is being developed as a treatment for advanced renal cell carcinoma and other types of cancer. Aveo Pharmaceuticals Inc is committed to advancing their pipeline of innovative therapies to address unmet medical needs.


   Company Address: 30 Winter Street Boston 2108 MA
   Company Phone Number: 400-0101   Stock Exchange / Ticker: AVEO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
TARA   -1.24%    
• View Complete Report
   



Product Service News

In-depth Analysis of Tivozanib’s Efficacy in Treating Advanced Renal Cell Carcinoma: Long-term Results from the Phase III TIVO-3 Trial

Published Tue, Feb 6 2024 1:10 PM UTC

AVEO Oncology recently announced the publication of significant results related to the long-term survival of patients with relapsed or refractory advanced Renal Cell Carcinoma (RCC) who have been treated with Tivozanib. The data, derived from a pivotal Phase III TIVO-3 Trial, provides valuable insights into the potential benefits of this treatment in enhancing the longevity ...
Clinical Study

AVEO Oncology Initiates Pivotal Clinical Trial to Evaluate Ficlatuzumab and ERBITUX Combination Therapy for HPV-Negative Head and Neck Cancer Patients

Published Tue, Jan 16 2024 12:30 PM UTC

AVEO Oncology, a subsidiary of LG Chem, has recently commenced enrollment for the FIERCE-HN trial, a highly anticipated phase 3 clinical trial. This global study aims to evaluate the efficacy and safety of AVEO s investigational antibody, Ficlatuzumab, in combination with ERBITUX (cetuximab), an anti-EGFR antibody. The trial specifically focuses on patients diagnosed with hu...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.82
Working Capital Ratio 2.37
Leverage Ratio (MRQ) 2.51
Total Debt to Equity 1.34
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.85 $
Revenues (TTM) 2.73 $
Cash Flow (TTM) 0.25 $
Cash 2.24 $
Book Value 0.83 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -
Receivable Turnover Ratio (TTM) 6.66
Inventory Turnover Ratio (TTM) 7.96
Asset Turnover Ratio (TTM) 0.94

Profitability Ratios Current
Gross Margin (MRQ) 86.98 %
Operating Margin (MRQ) -7.12 %
Net Margin (MRQ) -10.73 %
Net Cash Flow Margin (MRQ) 23.74 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.